Effect of Acupuncture on Patients With Crohn's Disease in Remission
Effect of Acupuncture on Crohn's Disease Via the Regulation of Trp-kyn Metabolism in Brain-gut Axis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Effect of acupuncture on symptoms (functional gastrointestinal symptoms, Fatigue, insomnia, depression, anxiety and perceived stress)of CD
- Effect of acupuncture on brain functional activity of CD
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Chunhui Bao, MD, PhD
- Phone Number: +862164395973
- Email: baochunhui789@126.com
Study Locations
-
-
-
Shanghai, China, 200030
- Shanghai Research Institute of Acupuncture and Meridian
-
Shanghai, China, 200437
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged 16-70;
- patients in remission (CDAI < 150);
- patients were not taking medication or were only taking one or more of the following drugs: [prednisone ≤15mg/d, azathioprine (≤1mg/kg/d), methotrexate (≤15mg/w) or mesalazine (≤4g/d)] and prednisone was used for at least 1 month, while azathioprine, methotrexate or mesalazine was used for at least 3 months;
- those who did not use TNF alpha and other preparations within 3 months before entering the study;
- those who have never experienced acupuncture;
- patients signing informed consent.
Exclusion Criteria:
- patients who are recently pregnant or in pregnancy or lactation;
- patients with serious organic diseases;
- patients diagnosed as psychosis;
- patients who take antibiotics, probiotics, traditional Chinese medicine and other drugs at the same time, or who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;
- severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;
- there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;
- patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;
- there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: acupuncture group
Receiving acupuncture and moxibustion
|
Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks.
CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion.
Hwato acupuncture device was used to blind the subjects, and had the deqi sensation.
The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
|
|
Sham Comparator: sham acupuncture group
Receiving sham acupuncture and sham moxibustion
|
Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks.
CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion.
Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation.
The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Fatigue Inventory (BFI-C)
Time Frame: Week 12
|
The mean change in BFI-C from baseline.
The higher the score, the worse the condition.
Greater than 0, the upper limit is 90.
|
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brain functional and structural changes
Time Frame: Week 12
|
measured by functional MRI
|
Week 12
|
|
Brief Fatigue Inventory (BFI-C)
Time Frame: Week 24,52
|
The mean change in BFI-C from baseline.
The higher the score, the worse the condition.
Greater than 0, the upper limit is 90.
|
Week 24,52
|
|
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
Time Frame: Week 12, 24,52
|
The mean change in FACIT-F from baseline.
The higher the score, the worse the condition.
The score range from 0 to 52.
|
Week 12, 24,52
|
|
Crohn's disease activity index (CDAI)score
Time Frame: Week 12, 24,36,48,52
|
The mean change in CDAI from baseline.
The higher the score, the worse the condition.
Greater than 0, no upper limit.
|
Week 12, 24,36,48,52
|
|
Inflammatory bowel disease questionnaire (IBDQ)
Time Frame: Week 12, 24 and 52
|
The mean change in IBDQ from baseline.
The higher the score, the worse the condition.The score is range from 32 to 224.
|
Week 12, 24 and 52
|
|
Hospital anxiety and depression scale (HADS)
Time Frame: Week 12, 24 and 52
|
The mean change in HADS from baseline.
The higher the score, the more serious the disease.
The depression and anxiety score is range from 0 to 21.
|
Week 12, 24 and 52
|
|
Patient Health Questionnaire Depression Scale (PHQ-9)
Time Frame: Week 12, 24 and 52
|
The mean change in PHQ-9 from baseline.
The higher the score, the more serious the disease.
The depression and anxiety score is range from 0 to 27.
|
Week 12, 24 and 52
|
|
Generalized Anxiety Disorder (GAD-7)
Time Frame: Week 12, 24 and 52
|
The mean change in gad-7 from baseline.
The higher the score, the more serious the disease.
The depression and anxiety score is range from 0 to 21.
|
Week 12, 24 and 52
|
|
The proportion of recurrences
Time Frame: Week 52
|
Defined as CDAI > 150 and increase ≥ 70 points or need to adjust drug to control disease condition.
|
Week 52
|
|
Colonoscopy or small bowel MR evaluation
Time Frame: Week 52
|
measured by colonoscopy (SES-CD score) or small bowel MR (MaRIA score)
|
Week 52
|
|
Laboratory tests
Time Frame: Week 12, 24, 36, and 52
|
Serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and platelet count (PLT)
|
Week 12, 24, 36, and 52
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Huangan Wu, MD, PhD, Shanghai Research Institute of Acupuncture and Meridian
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ZYS2019-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.